Alzheimer’s Drugs Race to FDA
On June 7, 2021, the FDA approved aducanumab (Aduhelm), an Alzheimer’s disease treatment targeting amyloid beta, using the accelerated approval pathway.
alzheimer's
alzheimer’s
Alzheimer’s